Book contents
- The Cambridge Handbook of Personality Disorders
- The Cambridge Handbook of Personality Disorders
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Part I Etiology
- Part II Models
- Part III Individual Disorders and Clusters
- Part IV Assessment
- Part V Treatment
- 17 Cognitive Behavioral Approaches
- 17a Applying a Cognitive-Behavioral, Principle-Based Approach to the Treatment of Personality Disorders: Commentary on Cognitive Behavioral Approaches
- 17b Implementation Challenges in Real World Settings: Commentary on Cognitive Behavioral Approaches
- 17c Further Considerations about Cognitive Behavioral Therapies and Personality Disorders: Author Rejoinder to Commentaries on Cognitive Behavioral Approaches
- 18 Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18a Contemporary Psychodynamic Treatments: Commentary on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18b Consideration of Commonalities in Distinct Models of Treatment for Individuals with Borderline Personality Disorder: Commentary on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18c Further Development of Three Key Issues: Author Rejoinder to Commentaries on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 19 Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19a A Functional Understanding of the Relationship between Personality and Clinical Diagnoses and Implications for Treatment Planning: Commentary on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19b The Need for Mechanistic Models to Translate Traits from Bench to Bedside: Commentary on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19c Simplicity and Dynamics of the ICD-11 Trait Qualifiers in Relation to Treatment: Author Rejoinder to Commentaries on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 20 Brief Therapeutic Approaches for Personality Disorders
- 20a What Knowledge Is Lacking on Brief Interventions for Personality Disorders and Why: Commentary on Brief Therapeutic Approaches for Personality Disorders
- 20b Short- and Long-Term Personality Disorder Treatment Studies Should Inform One Another: Commentary on Brief Therapeutic Approaches for Personality Disorders
- 20c Next Steps: Author Rejoinder to Commentaries on Brief Therapeutic Approaches for Personality Disorders
- 21 Recent Developments in the Pharmacologic Management of Personality Disorders
- 21a New Efforts towards Evidence-Informed Practice and Practice-Informed Research: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
- 21b Considerations Regarding the Pharmacological Management of Personality Disorders: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
- 21c Directions for Future Drug Trial Research: Author Rejoinder to Commentaries on Recent Developments in the Pharmacologic Management of Personality Disorders
- Index
- References
21a - New Efforts towards Evidence-Informed Practice and Practice-Informed Research: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
from Part V - Treatment
Published online by Cambridge University Press: 24 February 2020
Book contents
- The Cambridge Handbook of Personality Disorders
- The Cambridge Handbook of Personality Disorders
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Part I Etiology
- Part II Models
- Part III Individual Disorders and Clusters
- Part IV Assessment
- Part V Treatment
- 17 Cognitive Behavioral Approaches
- 17a Applying a Cognitive-Behavioral, Principle-Based Approach to the Treatment of Personality Disorders: Commentary on Cognitive Behavioral Approaches
- 17b Implementation Challenges in Real World Settings: Commentary on Cognitive Behavioral Approaches
- 17c Further Considerations about Cognitive Behavioral Therapies and Personality Disorders: Author Rejoinder to Commentaries on Cognitive Behavioral Approaches
- 18 Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18a Contemporary Psychodynamic Treatments: Commentary on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18b Consideration of Commonalities in Distinct Models of Treatment for Individuals with Borderline Personality Disorder: Commentary on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 18c Further Development of Three Key Issues: Author Rejoinder to Commentaries on Psychoanalytic/Psychodynamic Approaches to Personality Disorders
- 19 Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19a A Functional Understanding of the Relationship between Personality and Clinical Diagnoses and Implications for Treatment Planning: Commentary on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19b The Need for Mechanistic Models to Translate Traits from Bench to Bedside: Commentary on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 19c Simplicity and Dynamics of the ICD-11 Trait Qualifiers in Relation to Treatment: Author Rejoinder to Commentaries on Using DSM-5 and ICD-11 Personality Traits in Clinical Treatment
- 20 Brief Therapeutic Approaches for Personality Disorders
- 20a What Knowledge Is Lacking on Brief Interventions for Personality Disorders and Why: Commentary on Brief Therapeutic Approaches for Personality Disorders
- 20b Short- and Long-Term Personality Disorder Treatment Studies Should Inform One Another: Commentary on Brief Therapeutic Approaches for Personality Disorders
- 20c Next Steps: Author Rejoinder to Commentaries on Brief Therapeutic Approaches for Personality Disorders
- 21 Recent Developments in the Pharmacologic Management of Personality Disorders
- 21a New Efforts towards Evidence-Informed Practice and Practice-Informed Research: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
- 21b Considerations Regarding the Pharmacological Management of Personality Disorders: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders
- 21c Directions for Future Drug Trial Research: Author Rejoinder to Commentaries on Recent Developments in the Pharmacologic Management of Personality Disorders
- Index
- References
Summary
This commentary focuses on the current state and recent developments within the field of research on drug treatments for borderline personality disorder. From an evidence-based medicine perspective, the relevance of the currently available evidence for clinical practice is critically discussed. Some research/practice gaps are highlighted, like polypharmacy and the widespread use of quetiapine, which both lack supporting, sufficiently reliable evidence. Sources for the lack of practically relevant research are outlined, and the example of recent research on Olanzapine for patients with borderline personality disorder is amplified. Last, new initiatives are presented which aim at improving the value of research, like the REWARD alliance, the AllTrials campaign, and the James Lind alliance that guide, inform, and support the design, conduct, and publication of studies that are of relevancy to consumers and clinicians, and have the potential to transform healthcare. Some first encouraging results of these endeavors are presented.
Keywords
- Type
- Chapter
- Information
- The Cambridge Handbook of Personality Disorders , pp. 514 - 516Publisher: Cambridge University PressPrint publication year: 2020
References
ACTRN12615000705583. (n.d.). Evaluation of quetiapine as an adjunct treatment to psychotherapy for borderline personality disorder. Retrieved September 16, 2018, from www.anzctr.org.au/ACTRN12615000705583.aspxGoogle Scholar
ACTRN12616001192471. (n.d.). VERBATIM: A randomised controlled trial of aripiprazole for the treatment of auditory verbal hallucinations in borderline personality disorder. Retrieved September 16, 2018, from www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371038Google Scholar
EudraCT Number 2012-003136-23. (n.d.). EudraCT Number 2012-003136-23 – Clinical trial results – EU Clinical Trials Register. Retrieved August 14, 2018, from www.clinicaltrialsregister.eu/ctr-search/trial/2012-003136-23/resultsGoogle Scholar
NCT00254748. (n.d.). Verkes Borderline Study: The effect of quetiapine on borderline personality disordered patients. Retrieved September 16, 2018, from https://ClinicalTrials.gov/show/NCT00254748Google Scholar
Black, D. W., Zanarini, M. C., Romine, A., Shaw, M., Allen, J., & Schulz, S. C. (2014). Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 171(11), 1174–1182.Google Scholar
Bozzatello, P., Rocca, P., Uscinska, M., & Bellino, S. (2017). Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: An open-label randomized controlled trial. CNS Drugs, 31(9), 809–819.Google Scholar
Bridler, R., Häberle, A., Müller, S. T., Cattapan, K., Grohmann, R., Toto, S., … Greil, W. (2015). Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 25(6), 763–772.CrossRefGoogle ScholarPubMed
Brown, T. (2013). It’s time for AllTrials registered and reported. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons. https://doi.org/10.1002/14651858.ED000057Google Scholar
Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. Lancet, 374(9683), 86–89.Google Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Byford, S., Cunningham, G., Gakhal, K., … Reilly, J. G. (2015). Lamotrigine versus inert placebo in the treatment of borderline personality disorder: Study protocol for a randomized controlled trial and economic evaluation. Trials, 16, 308. https://doi.org/10.1186/s13063–015-0823-xGoogle Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Cunningham, G., Dale, O., Ganguli, P., … Reilly, J. G. (2018a). The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: A randomized placebo-controlled trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2018.17091006CrossRefGoogle Scholar
Crawford, M. J., Sanatinia, R., Barrett, B., Cunningham, G., Dale, O., Ganguli, P., … Reilly, J. G. (2018b). Lamotrigine for people with borderline personality disorder: A RCT. Health Technology Assessment (Winchester, England), 22(17), 1–68. https://doi.org/10.3310/hta22170.Google Scholar
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., … International Committee of Medical Journal Editors (2004). Clinical trial registration: A statement from the International Committee of Medical Journal Editors. The New England Journal of Medicine, 351(12), 1250–1251.CrossRefGoogle ScholarPubMed
Gunderson, J. G., & Choi-Kain, L. W. (2018). Medication management for patients with borderline personality disorder. American Journal of Psychiatry, 175(8), 709–711.Google Scholar
Jariani, M., Saaki, M., Nazari, H., & Birjandi, M. (2010). The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatria Danubina, 22(4), 544–547.Google Scholar
Macleod, M. R., Michie, S., Roberts, I., Dirnagl, U., Chalmers, I., Ioannidis, J. P. A., … Glasziou, P. (2014). Biomedical research: Increasing value, reducing waste. Lancet, 383(9912), 101–104.CrossRefGoogle ScholarPubMed
National Health and Medical Research Council, Canberra, Australia [NHMRC]. (2013). Clinical Practice Guideline for the Management of Borderline Personality Disorder. Retrieved August 27, 2018 from www.nhmrc.gov.au/guidelines/publications/mh25.Google Scholar
National Institute for Health and Care Excellence, UK [NICE]. (2009). NICE Clinical Guideline 78. Borderline Personality Disorder: Treatment and Management. Full Guideline (January 2009). Retrieved August 27, 2018 from www.nice.org.uk/guidance/cg78.Google Scholar
Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa, G. F., Bachler, E., … Kaplan, P. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163(5), 833–838.Google Scholar
Petit-Zeman, S., Firkins, L., & Scadding, J. W. (2010). The James Lind Alliance: Tackling research mismatches. Lancet, 376(9742), 667–669.CrossRefGoogle Scholar
Reich, D. B., Zanarini, M. C., & Bieri, K. A. (2009). A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology, 24(5), 270–275.Google ScholarPubMed
Sackett, D. L., Rosenberg, W. M., Gray, J. A., Haynes, R. B., & Richardson, W. S. (1996). Evidence based medicine: What it is and what it isn’t. BMJ, 312(7023), 71–72.CrossRefGoogle ScholarPubMed
Shafti, S., & Kaviani, H. (2015). A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder. Klinik Psikofarmakoloji Bülteni/Bulletin of Clinical Psychopharmacology, 25(1), 38–43.Google Scholar
Shafti, S., & Shahveisi, B. (2010). Olanzapine versus haloperidol in the management of borderline personality disorder: A randomized double-blind trial. Journal of Clinical Psychopharmacology, 30(1), 44–47.CrossRefGoogle ScholarPubMed
Simera, I., Moher, D., Hirst, A., Hoey, J., Schulz, K. F., & Altman, D. G. (2010). Transparent and accurate reporting increases reliability, utility, and impact of your research: Reporting guidelines and the EQUATOR Network. BMC Medicine, 8, 24. https://doi.org/10.1186/1741-7015-8-24CrossRefGoogle ScholarPubMed
Stoffers, J. M., & Lieb, K. (2015). Pharmacotherapy for borderline personality disorder: Current evidence and recent trends. Current Psychiatry Reports, 17(1), 534–545.CrossRefGoogle ScholarPubMed
Stoffers, J., Völlm, B. A., Rucker, G., Timmer, A., Huband, N., & Lieb, K. (2010). Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews, 6 [CD005653]. https://doi.org/10.1002/14651858.CD005653.pub2Google Scholar
Stoffers‐Winterling, J. M., Storebø, O. J., Völlm, B. A., Mattivi, J. T., Nielsen, S. S., Kielsholm, M. L., … Lieb, K. (2018). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews, 2. https://doi.org/10.1002/14651858.CD012956Google Scholar
Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W. K., Loew, T. H., & Nickel, M. K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19(3), 287–291.Google Scholar
Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65(7), 903–907.Google Scholar
Zanarini, M. C., Frankenburg, F. R., Reich, D. B., Harned, A. L., & Fitzmaurice, G. M. (2015). Rates of psychotropic medication use reported by borderline patients and Axis II Comparison subjects over 16 years of prospective follow-up. Journal of Clinical Psychopharmacology, 35(1), 63–67.Google Scholar